We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
News

PathoQuest Announces New Leadership at the Board of Directors

Rectangle Image
News

PathoQuest Announces New Leadership at the Board of Directors

Read time:
 

PathoQuest announced new leadership at the Board of directors effective immediately. The shareholders have appointed Benedikt von Braunmühl as Chairman of the Board of Directors. This announcement follows the appointment of Jean-François Brepson as President & Chief Executive Officer in December 2015 and is another important step in the transformation of PathoQuest from a cutting edge technology platform to a commercial organization.

"I am welcoming the new Chairman of the Board, who will bring strong strategic and commercial expertise in the diagnostic, vaccines and pharmaceutical marketplace to us, said Jean-François Brepson President & Chief Executive Officer of PathoQuest."

Benedikt von Braunmühl has over 20 years of leadership experience in the Diagnostic, Life Sciences, Vaccines and Pharmaceutical industry. He has a Bachelor in Business Administration from the Lorange Institute of Business in Zürich. He was Senior Vice President, Head of Global Commercial Operations and member of the Executive Committee at QIAGEN, one of the leaders in the Diagnostic and Life Science Industry.

Prior to QIAGEN he worked at Chiron Vaccines - later Novartis Vaccines & Diagnostics - as Director Marketing and Commercial Head for Latin America. Before joining Chiron he held different positions in investment banking and the pharmaceutical industry in Germany and abroad.

“I am very honored to be appointed at PathoQuest. I am convinced that its platform is a breakthrough in the diagnostic space, which will help the medical community to provide targeted treatment of infectious diseases to patients. An impressive demonstration has been made in a recent comparative clinical study with classical methods in immunocompromised patients. I will support Jean-François and his teams to accelerate market launch of this revolutionizing molecular methodology.” said Benedikt

“The appointment of Benedikt will further accelerate PathoQuest’s development to its next phase of global commercialization. With its unique and disruptive technology, we are very confident in the growth potential of PathoQuest” said Thierry Laugel, Managing Partner at Kurma Partners.

Advertisement